文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

关于副内脏利什曼病皮肤利什曼病的病例报告:一个未解之谜。

A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.

机构信息

Department of Medicine, Sir Salimullah Medical College Mitford Hospital, Dhaka, Bangladesh.

Government Employee Hospital, Dhaka, Bangladesh.

出版信息

BMC Infect Dis. 2023 Dec 18;23(1):885. doi: 10.1186/s12879-023-08918-1.


DOI:10.1186/s12879-023-08918-1
PMID:38110894
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10729440/
Abstract

BACKGROUND: Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis that occurs 2-3 years after an apparently successful treatment of visceral leishmaniasis (VL). In rare cases, PKDL occurs concurrently with VL and is characterized by fever, splenomegaly, hepatomegaly or lymphadenopathy, and poor nutritional status and is known as Para-kala-azar dermal leishmaniasis (Para-KDL). Co-association of active VL in PKDL patients is documented in Africa, but very few case reports are found in South Asia. We present a case of Para-kala-azar Dermal Leishmaniasis (Para-KDL) in a 50-year-old male patient with a history of one primary Visceral Leishmaniasis (VL) and 2 times relapse of Visceral Leishmaniasis (VL). The patient presented with fever, skin lesions, and hepatosplenomegaly. Laboratory tests revealed LD bodies in the slit skin smear and splenic biopsy. The patient was treated with two cycles of Amphotericin B with Miltefosine in between cycles for 12 weeks to obtain full recovery. CONCLUSION: This case report serves as a reminder that Para-kala-azar dermal leishmaniasis can develop as a consequence of prior visceral leishmaniasis episodes, even after apparently effective therapy. Since para-kala-azar is a source of infectious spread, endemics cannot be avoided unless it is effectively recognized and treated.

摘要

背景: 黑热病后皮肤利什曼病(PKDL)是一种皮肤病,发生在内脏利什曼病(VL)治疗后 2-3 年。在罕见情况下,PKDL 与 VL 同时发生,其特征为发热、脾肿大、肝肿大或淋巴结病以及营养不良,并称为副黑热病皮肤利什曼病(Para-KDL)。在非洲,有记录表明 PKDL 患者并发活动性 VL,但在南亚,很少有病例报告。我们报告了一名 50 岁男性患者的 Para-kala-azar 皮肤利什曼病(Para-KDL)病例,该患者有一次原发性内脏利什曼病(VL)病史和两次内脏利什曼病(VL)复发。该患者表现为发热、皮肤损伤和肝脾肿大。实验室检查显示皮肤划痕液中有 LD 体和脾活检中的利什曼原虫。该患者接受了两个疗程的两性霉素 B 和米替福新治疗,疗程之间间隔 12 周,以获得完全康复。

结论: 本病例报告提醒人们,副黑热病皮肤利什曼病可由先前的内脏利什曼病发作引起,即使在经过明显有效的治疗后也是如此。由于副黑热病是传染性传播的来源,除非能够有效识别和治疗,否则无法避免流行。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/9b1a0fcef9e8/12879_2023_8918_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/f8ba1cbe9208/12879_2023_8918_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/4c240e73f9bc/12879_2023_8918_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/f39a433535c3/12879_2023_8918_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/56b3782d7608/12879_2023_8918_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/9b1a0fcef9e8/12879_2023_8918_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/f8ba1cbe9208/12879_2023_8918_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/4c240e73f9bc/12879_2023_8918_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/f39a433535c3/12879_2023_8918_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/56b3782d7608/12879_2023_8918_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a6b/10729440/9b1a0fcef9e8/12879_2023_8918_Fig5_HTML.jpg

相似文献

[1]
A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.

BMC Infect Dis. 2023-12-18

[2]
Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.

BMC Infect Dis. 2015-11-23

[3]
VL-HIV co-infection with Leishmania containing skin lesions resembling para-kala-azar dermal leishmaniasis.

PLoS Negl Trop Dis. 2024-8

[4]
Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.

Rev Soc Bras Med Trop. 2018

[5]
Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.

Am J Trop Med Hyg. 2009-3

[6]
Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.

Acta Trop. 2021-11

[7]
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.

Trop Med Int Health. 2012-8-12

[8]
Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.

PLoS Negl Trop Dis. 2014-1-2

[9]
Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.

J Postgrad Med. 2013

[10]
Revisiting the diagnosis and treatment of Para Kala-azar Dermal Leishmaniasis in the endemic foci of Bangladesh.

PLoS One. 2023

引用本文的文献

[1]
Recombinant Leishmania-activated C kinase as a novel antigenic candidate for immuno-diagnosis of visceral leishmaniasis occurring in India and Brazil.

Infect Dis Poverty. 2025-7-9

[2]
Overview of Research on Leishmaniasis in Africa: Current Status, Diagnosis, Therapeutics, and Recent Advances Using By-Products of the Sargassaceae Family.

Pharmaceuticals (Basel). 2024-4-18

本文引用的文献

[1]
Para Kala-Azar Dermal Leishmaniasis: A Case Report.

Cureus. 2023-1-12

[2]
Cutaneous and Mucocutaneous Leishmaniasis.

Actas Dermosifiliogr (Engl Ed). 2021-5-11

[3]
Emerging therapeutic targets for treatment of leishmaniasis.

Expert Opin Ther Targets. 2018-5-9

[4]
Para-kala-azar dermal Leishmaniasis cases in Indian subcontinent - A case series.

Pathog Glob Health. 2016

[5]
The immunology of post-kala-azar dermal leishmaniasis (PKDL).

Parasit Vectors. 2016-8-23

[6]
Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.

Clin Infect Dis. 2012-5-9

[7]
Liposomal amphotericin B for the treatment of visceral leishmaniasis.

Clin Infect Dis. 2006-10-1

[8]
Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.

Int J Dermatol. 2005-6

[9]
Visceral leishmaniasis with concomittant post kala-azar dermal leishmaniasis responds to oral sitamaquine: case report.

East Afr Med J. 2003-8

[10]
Post-kala-azar dermal leishmaniasis.

Lancet Infect Dis. 2003-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索